Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21675145 | 0.86 | ALDH1A1 (0.46) | TSHRALDH1A1ALOX5MAPTSMN1; SMN2 | |
| SCHEMBL4045487 | 0.83 | TSHR (0.50) | TSHRALDH1A1ALOX5MAPTSMN1; SMN2 | |
| SCHEMBL5145660 | 0.78 | TSHR (0.58) | TSHRALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL466109 | 0.77 | ALDH1A1 (0.50) | TSHRALDH1A1ALOX5MAPTSMN1; SMN2 | |
| SCHEMBL20521373 | 0.77 | ALDH1A1 (0.50) | TSHRALDH1A1ALOX5MAPTSMN1; SMN2 | |
| SCHEMBL381981 | 0.75 | TSHR (0.54) | TSHRALDH1A1ALOX5HTT | |
| SCHEMBL5746831 | 0.75 | NPC1 (0.49) | TSHRALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL16334855 | 0.74 | NR1H4 (0.48) | TSHRALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL16334854 | 0.74 | NR1H4 (0.48) | TSHRALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL22335173 | 0.74 | MAPT (0.41) | TSHRALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719605-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.4) Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| WO-2024246862-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | TSHR 4153/4885ALDH1A1 1151/4885ALOX5 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.